No plans yet to list in China, political impact minimized: Gracell Biotechnologies CEO

William Cao, CEO of Nasdaq-listed Chinese cancer biotech firm Gracell Biotechnologies says any impact coming from U.S.-China tensions will be minimized for his company; and they are embracing potential partnerships with multinational players to develop in the U.S. and Europe.
Mon, Jan 11 20211:55 AM EST